Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.

[1]  X. Chen,et al.  Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma , 2023, Frontiers in Immunology.

[2]  A. Addeo,et al.  RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. , 2023, Pharmacology & therapeutics.

[3]  Z. Baloch,et al.  The 2022 WHO Classification of thyroid tumors: novel concepts in nomenclature and grading. , 2022, Endocrine-related cancer.

[4]  E. Arvat,et al.  Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective , 2022, Cancer management and research.

[5]  M. Stang,et al.  Medullary thyroid cancer with RET V804M mutation: more indolent than expected? , 2022, Surgery.

[6]  Jiayi Li,et al.  Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review , 2022, Frontiers in Immunology.

[7]  T. Higashiyama,et al.  Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). , 2022, European journal of cancer.

[8]  Youwen Zhu,et al.  Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis , 2022, Frontiers in Endocrinology.

[9]  M. Alevizaki,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. , 2022, European journal of endocrinology.

[10]  Jiang Liu,et al.  FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  S. Filetti,et al.  ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Elisei,et al.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine , 2022, Frontiers in Endocrinology.

[13]  C. Bourque,et al.  The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers , 2022, Nature Communications.

[14]  Hezhi Fang,et al.  Thyroid Cancer-Associated Mitochondrial DNA Mutation G3842A Promotes Tumorigenicity via ROS-Mediated ERK1/2 Activation , 2022, Oxidative medicine and cellular longevity.

[15]  E. Grande,et al.  Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies. , 2022, Cancer treatment reviews.

[16]  A. Drilon,et al.  Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma , 2022, European journal of endocrinology.

[17]  V. Seshan,et al.  Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. , 2022, Thyroid : official journal of the American Thyroid Association.

[18]  Mimi I Hu,et al.  RET kinase inhibitors for RET-altered thyroid cancers , 2022, Therapeutic advances in medical oncology.

[19]  S. Qin,et al.  Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer , 2021, JAMA oncology.

[20]  Yujiao Wu,et al.  DNA Methylation Age Drift Is Associated with Poor Outcomes and De-Differentiation in Papillary and Follicular Thyroid Carcinomas , 2021, Cancers.

[21]  P. Niccoli,et al.  Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. , 2021, European journal of cancer.

[22]  Yuan Zhang,et al.  A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer , 2021, Clinical Cancer Research.

[23]  E. Hitre,et al.  Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[24]  A. Mansfield,et al.  Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. , 2021, The lancet. Diabetes & endocrinology.

[25]  M. Schlumberger,et al.  Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Douglas B. Johnson,et al.  Endocrine toxicities of immune checkpoint inhibitors , 2021, Nature Reviews Endocrinology.

[27]  B. Ahn,et al.  Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS , 2021, Theranostics.

[28]  A. Colao,et al.  Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer? , 2021, Frontiers in Endocrinology.

[29]  Yuan Zhang,et al.  Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial , 2021, Clinical Cancer Research.

[30]  Jun Liang,et al.  Long-term results of phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer. , 2021, The Journal of clinical endocrinology and metabolism.

[31]  B. Robinson,et al.  Multikinase inhibitors in thyroid cancer: timing of targeted therapy , 2021, Nature Reviews Endocrinology.

[32]  M. Boerries,et al.  Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma , 2021, Thyroid.

[33]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[34]  M. Schlumberger,et al.  Current practice in patients with differentiated thyroid cancer , 2020, Nature Reviews Endocrinology.

[35]  S. Benvenga,et al.  Molecular targets of tyrosine kinase inhibitors in thyroid cancer. , 2020, Seminars in cancer biology.

[36]  B. Taylor,et al.  Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib , 2020, Clinical Cancer Research.

[37]  Fangfang Zhou,et al.  Non-coding RNA in thyroid cancer - Functions and mechanisms. , 2020, Cancer letters.

[38]  Rongfu Wang,et al.  Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter, phase II trial. , 2020, Thyroid : official journal of the American Thyroid Association.

[39]  A. Drilon,et al.  Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. , 2020, The New England journal of medicine.

[40]  E. Sturgis,et al.  Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. , 2020, JAMA oncology.

[41]  L. Bastholt,et al.  Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Y. Zhang,et al.  Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: A multicenter, open-label, Phase II trial. , 2020, Thyroid : official journal of the American Thyroid Association.

[43]  N. Fleeman,et al.  Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. , 2020, Health technology assessment.

[44]  N. Busaidy.  The Year in Medical Thyroidology Review: Current Challenges and Future Directions. , 2019, Thyroid : official journal of the American Thyroid Association.

[45]  M. Cabanillas,et al.  Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. , 2019, Endocrine reviews.

[46]  M. Papotti,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Bin Xu,et al.  Molecular Alterations in Thyroid Carcinoma. , 2019, Surgical pathology clinics.

[48]  F. Basolo,et al.  Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing , 2019, iScience.

[49]  L. Kowalski,et al.  DNA methylation-based method to differentiate malignant from benign thyroid lesions. , 2019, Thyroid : official journal of the American Thyroid Association.

[50]  A. Antonelli,et al.  The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition , 2019, International journal of molecular sciences.

[51]  L. Ming,et al.  Leukocyte Mitochondrial DNA Copy Number and Risk of Thyroid Cancer: A Two-Stage Case-Control Study , 2019, Front. Endocrinol..

[52]  G. Freeman,et al.  Anti‐PD‐1/PD‐L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer , 2019, International journal of cancer.

[53]  J. Shah,et al.  Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. , 2019, Thyroid : official journal of the American Thyroid Association.

[54]  F. D. De Braud,et al.  Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer , 2019, BMC Cancer.

[55]  C. Carroll,et al.  Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. , 2019, Health technology assessment.

[56]  K. Nakano,et al.  A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. , 2019, Future oncology.

[57]  Lin Zhao,et al.  The safety of apatinib for the treatment of gastric cancer , 2018, Expert opinion on drug safety.

[58]  B. Prabhakar,et al.  Therapeutic advances in anaplastic thyroid cancer: a current perspective , 2018, Molecular Cancer.

[59]  G. Freeman,et al.  Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer , 2018, British Journal of Cancer.

[60]  V. Seshan,et al.  Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. , 2018, The Journal of clinical endocrinology and metabolism.

[61]  D. van Nostrand,et al.  Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications. , 2018, Thyroid : official journal of the American Thyroid Association.

[62]  E. Sturgis,et al.  Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma , 2018, Journal of Immunotherapy for Cancer.

[63]  A. Drilon,et al.  Selective RET kinase inhibition for patients with RET-altered cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  Shuliang Song,et al.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance , 2018, Molecular Cancer.

[65]  J. Wright,et al.  Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  K. Nakano,et al.  Lenvatinib for Anaplastic Thyroid Cancer , 2017, Front. Oncol..

[67]  J. Beermann,et al.  Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. , 2016, Physiological reviews.

[68]  M. Brose,et al.  Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[69]  Omid C Farokhzad,et al.  Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer , 2016, Proceedings of the National Academy of Sciences.

[70]  C. Pritchard,et al.  TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer , 2016, Oncogene.

[71]  R. McIntyre,et al.  Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. , 2016, The Journal of clinical endocrinology and metabolism.

[72]  G. Daniels,et al.  Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib—Response , 2015, Clinical Cancer Research.

[73]  V. Leite,et al.  RAS proto-oncogene in medullary thyroid carcinoma. , 2015, Endocrine-related cancer.

[74]  S. Lim,et al.  An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. , 2015, European Journal of Cancer.

[75]  E. Palmer,et al.  Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib , 2014, Clinical Cancer Research.

[76]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[77]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[78]  M. Luster,et al.  Definition and management of radioactive iodine-refractory differentiated thyroid cancer. , 2014, The lancet. Diabetes & endocrinology.

[79]  C. Serrano-Nascimento,et al.  Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors. , 2014, The Journal of clinical endocrinology and metabolism.

[80]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Wright,et al.  Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. , 2013, Thyroid : official journal of the American Thyroid Association.

[82]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[83]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Marina N. Nikiforova,et al.  Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.

[85]  A. El‐Naggar,et al.  IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer , 2010, Clinical Cancer Research.

[86]  S. Wajner,et al.  Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.

[87]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[88]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[89]  P. Hou,et al.  Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3‐kinase/AKT signaling pathway in thyroid tumors , 2008, Cancer.

[90]  C. Larsson,et al.  Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. , 2008, Endocrine-related cancer.

[91]  P. Hou,et al.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.

[92]  G. Brent,et al.  Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. , 2006, Endocrine-related cancer.

[93]  Nancy D Perrier,et al.  RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. , 2005, Thyroid : official journal of the American Thyroid Association.

[94]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[95]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[96]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[97]  C. Esapa,et al.  Prevalence of Ras mutations in thyroid neoplasia , 1999, Clinical endocrinology.

[98]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[99]  G. Daniels,et al.  Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial. , 2022, Thyroid : official journal of the American Thyroid Association.

[100]  S. Ou,et al.  Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. , 2018, Cancer discovery.

[101]  P. Wen,et al.  Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  F. Pattou,et al.  MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. , 2014, Thyroid : official journal of the American Thyroid Association.

[103]  T. Carling,et al.  Thyroid cancer. , 2014, Annual review of medicine.

[104]  A. Sakamoto,et al.  Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. , 2000, Pathology, research and practice.